Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients who have received allogeneic hematopoietic stem cell transplantation for hematological diseases: An observational study.
Not Applicable
Completed
- Conditions
- Patients who have received allogeneic hematopoietic stem cell transplantation for hematological diseases
- Registration Number
- JPRN-UMIN000046044
- Lead Sponsor
- Kobe City Medical Center General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) Those who are judged by the principal investigator or sub-investigator to be inappropriate for participation in the study. 2) Patients with a history of COVID-19 3) Patients who are unable to communicate with others
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method